Lyell Immunopharma, Inc. — Director's Dealing 2021

Sep 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2021-09-13

Reporting Person: Homans Elizabeth (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-13	Option (right to buy)	$16.05	A	1370469	Acquired	2031-09-12	Common Stock (1370469)	Direct

Footnotes

F1: The shares vest in equal monthly installments over the forty-eight months following September 13, 2021.